Phase Ib/II Study of Glofitamab with Atezolizumab or Polatuzumab in B-Cell NHL
A Phase Ib/II study is assessing the safety and efficacy of Glofitamab combined with Atezolizumab or Polatuzumab in relapsed/refractory B-cell NHL.
Phase III
Oncology / B-Cell Non-Hodgkin's Lymphoma
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase Ib/II study of Glofitamab in combination with Atezolizumab or Polatuzumab is critical as it could significantly enhance Hoffmann-La Roche's competitive positioning in the B-cell Non-Hodgkin's Lymphoma treatment landscape. Positive trial outcomes may lead to increased market share and influence future treatment protocols.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the determination of MTD/RP2D and initial efficacy results from the trial.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.